Investor Presentaiton
Investor presentation
First three months of 2017
Slide 14
Significant regulatory news flow in 2017
Project
TresibaⓇ
Q1 2017
Once-weekly semaglutide
EU SWITCH approval ✓
Japan submission √
Victoza®
Fast-acting insulin aspart
Semaglutide obesity
N9-GP
EU approval
US resubmission
Q2 2017
US & EU submission of
DEVOTE data
N9-GP CHMP opinion √
US regulatory decision
Japan submission
Phase 1 data
Results available
Q3 2017
Regulatory milestone
Q4 2017
US label update decision
for SWITCH
SUSTAIN 7
phase 3b data
LEADER CHMP opinion &
US regulatory decision
US regulatory decision
Phase 2 data
US regulatory decision
CHMP opinion
Concizumab
Somapacitan
Diabetes
Obesity
Haemophilia
Growth disorders
1 Study conducted in adult growth hormone disorder
CHMP: Committee for Medicinal Products for Human Use in Europe
changing
diabetes®
REAL 1 phase 3a data¹
novo nordiskView entire presentation